13 June 2019

In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast.

Pazopanib is taken fasted in a fixed oral daily dose of 800mg. We hypothesized that ingesting pazopanib with food may improve patients' comfort and reduce gastro-intestinal adverse events. Therefore we investigated the bio-equivalent dose of pazopanib when taken with food compared to 800mg pazopanib taken fasted. In addition we investigated the differences in GI-toxicity, patient satisfaction and patient's preference for either intake. The intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast. 

Publication
The effect of using pazopanib with food vs fasted on pharmacokinetics, patient safety and preference (DIET study).
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Floor Lubberman is member of theme Urological cancers.

Related news items


Lowering cholesterol is not enough to reduce hyperactivity of the immune system

14 June 2019

In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provides a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.

read more

New cause for vaginal yeast infections discovered

13 June 2019

Martin Jaeger, theme Infectious diseases and global health, and colleagues, identified SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Their findings were published in Science Translational Medicine.

read more

Internal KWF review procedure 2020

13 June 2019

In agreement with the existing policy the research board and Radboud Center for Oncology have decided to continue with the mandatory internal review procedure for KWF grant applications.

read more

A personal touch of Johan van der Vlag

13 June 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Johan van der Vlag.

read more

Peter van der Kraan new theme leader Inflammatory diseases

13 June 2019

It is our pleasure to introduce Peter van der Kraan from the Dept. of Rheumatology, as the new leader of our theme Inflammatory diseases. As such he will be the successor of Irma Joosten who has done an outstanding job in the last years as theme leader, for which we thank her wholeheartedly.

read more

RIHS PhD candidates visit Philips Healthcare

13 June 2019

On 7 June the RIHS PhD council organized an excursion to Philips Healthcare in Best.

read more